# Manifold Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/manifold-biotechnologies

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.manifold.bio
- Total disclosed funding: $45M
- Latest round: Series A (May 27, 2022)
- Investors on record: 10

## About

Manifold Biotechnologies, Inc. is a biotechnology firm focused on creating tissue-targeted biologics using its proprietary mDesign platform, combining high-throughput screening with AI to enhance drug development.Founded in 2019 in Boston, US, Manifold Biotechnologies, Inc. specializes in the development of biologics for drug delivery. The company has seen a focus on advanced protein engineering and has reported three funding deals, with its latest funding round being in May 2022, when it raised USD 40.000 mn in a Series A led by Triatomic Capital, backed by notable investors including FPV Ventures, Fifty Years, and Tencent Investment. The firm is led by CEO Gleb Kuznetsov, who co-founded the company alongside Pierce Ogden and Shane Lofgren.Manifold Bio specializes in the design and development of tissue-targeted biologics through its proprietary mDesign platform. This platform enables high-throughput in vivo screening and AI-guided protein design, allowing evaluation of biodistribution and pharmacokinetics of protein-based therapeutics. Key products include engineered protein delivery vehicles known as shuttles, which target neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis, serving clients within the pharmaceutical and biotechnology sectors globally.Manifold Bio generates revenue through strategic partnerships that leverage its mDesign platform and shuttle library to assist pharmaceutical companies in developing targeted therapies. The revenue model is based on B2B agreements, which may include upfront fees, milestone payments, and royalties on future sales. Additionally, customized services related to its core technologies may also contribute to revenue, though specific pricing remains proprietary.Following the recent Series A funding round in May 2022, where the company secured USD 40.000 mn, Manifold Biotechnologies, Inc. plans to utilize this capital to advance its internal drug programs and expand its protein engineering platform. The company intends to enhance its current offerings and explore additional partnerships, focusing on broadening its market presence in North America, Europe, and Asia by developing new products targeted at specific therapeutic applications.

## Funding rounds

- Series A, May 27, 2022, $40M — Tencent Investment, Horizons Ventures, GettyLab, Playground Ventures, Section 32, Fifty Years, FPV Ventures, Triatomic Capital
- Seed, Sep 8, 2020, $5.4M — GettyLab, Playground Global, LLC, Fifty Years, The Allston Venture Fund

## Investors

- GettyLab (https://capitalatlas.ai/funds/gettylab) — Seed, Series A
- Playground Global, LLC — Seed
- Fifty Years (https://capitalatlas.ai/funds/fifty-years) — Seed, Series A
- The Allston Venture Fund (https://capitalatlas.ai/funds/the-allston-venture-fund) — Seed
- Tencent Investment — Series A
- Horizons Ventures — Series A
- Playground Ventures (https://capitalatlas.ai/funds/playground-ventures) — Series A
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series A
- FPV Ventures (https://capitalatlas.ai/funds/fpv-ventures) — Series A
- Triatomic Capital (https://capitalatlas.ai/funds/triatomic-capital) — Series A